FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306320223> ?p ?o ?g. }

• W4306320223 abstract "Abstract Background Atrial fibrillation patients with a history of major bleeding (MB) are at high risk of future bleeding events; this history was an exclusion criterion in pivotal phase 3 trials of anticoagulation for stroke prevention. Real-world edoxaban effectiveness and safety in patients with a history of MB were analysed from the global ETNA programme. Purpose To compare edoxaban effectiveness and safety in AF patients with or without an MB history. Methods The Global ETNA-AF programme (EU: NCT02944019, Japan: UMIN000017011, South Korea/Taiwan: NCT02951039) integrates data from multiple prospective, observational, noninterventional regional studies of AF patients treated with edoxaban for stroke prevention. This snapshot analysis summarises global baseline characteristics and 2-year annualised rates of all-cause death, cardiovascular death, stroke (haemorrhagic, ischaemic, any), and bleeding (including MB, major gastrointestinal bleeding [MGIB], intracranial haemorrhage [ICH], clinically relevant nonmajor bleeding, and any bleeding) in patients with or without MB history. Results Data from 27,333 patients (479 with MB history and 26,854 without) from Europe, Japan, South Korea, and Taiwan were analysed. Patients with MB history were significantly older (P&lt;0.0001) and more likely to be ≥75 years of age (P=0.0003), to be male (P=0.024), and to have a lower body weight and creatinine clearance (P&lt;0.0001 for both) (Table). Globally, antiplatelet use was significantly higher in patients with MB history compared with patients without (P=0.005). Patients with MB history were more likely to have previously diagnosed heart failure (HF, P=0.001) and to receive 30 mg vs 60 mg edoxaban at baseline (P&lt;0.0001). Hazard ratios for effectiveness and safety outcomes are shown in the Figure. Patients with MB history had significantly higher annualised rates of all-cause death (5.7% vs 3.1%; P&lt;0.0001), ischaemic stroke (1.8% vs 0.7%; P=0.002), and any stroke (3.1% vs 0.9%; P&lt;0.0001) than patients without MB history. Patients with MB history also had significantly higher annualised rates of MB (3.6% vs 1.0%; P&lt;0.0001), MGIB (1.5% vs 0.5%; P=0.001), ICH (1.5% vs 0.3%; P&lt;0.0001), fatal bleeding (0.9% vs 0.2%; P&lt;0.0001), and fatal ICH (0.5% vs 0.1%; P=0.0002). Among patients with MB history, the annualised rate of ICH did not differ between patients with ICH history (1.42%/yr) vs without (1.65%/yr); whereas the annualised rate of MGIB was significantly higher in patients with MGIB history vs without (4.14%/yr vs 1.08%/yr; P=0.0337). Conclusions Patients with AF receiving edoxaban and who have a history of MB are more likely elderly, male, and have comorbidities, including HF. These patients are also more susceptible to any adverse cardiovascular event. ICH event rates were not higher in patients with prior ICH than those with non-ICH major bleedings, whereas history of MGIB was associated with a high risk of MGIB recurrence. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo" @default.
• W4306320223 created "2022-10-16" @default.
• W4306320223 creator A5012356817 @default.
• W4306320223 creator A5019501726 @default.
• W4306320223 creator A5041953660 @default.
• W4306320223 creator A5046869520 @default.
• W4306320223 creator A5047325459 @default.
• W4306320223 creator A5052435380 @default.
• W4306320223 creator A5055983723 @default.
• W4306320223 creator A5067459890 @default.
• W4306320223 creator A5070215876 @default.
• W4306320223 date "2022-10-01" @default.
• W4306320223 modified "2023-09-30" @default.
• W4306320223 title "Two-year effectiveness and safety outcomes in 27,333 edoxaban-treated patients with and without a history of major bleeding from the Global ETNA-AF programme" @default.
• W4306320223 doi "https://doi.org/10.1093/eurheartj/ehac544.2701" @default.
• W4306320223 hasPublicationYear "2022" @default.
• W4306320223 type Work @default.
• W4306320223 citedByCount "0" @default.
• W4306320223 crossrefType "journal-article" @default.
• W4306320223 hasAuthorship W4306320223A5012356817 @default.
• W4306320223 hasAuthorship W4306320223A5019501726 @default.
• W4306320223 hasAuthorship W4306320223A5041953660 @default.
• W4306320223 hasAuthorship W4306320223A5046869520 @default.
• W4306320223 hasAuthorship W4306320223A5047325459 @default.
• W4306320223 hasAuthorship W4306320223A5052435380 @default.
• W4306320223 hasAuthorship W4306320223A5055983723 @default.
• W4306320223 hasAuthorship W4306320223A5067459890 @default.
• W4306320223 hasAuthorship W4306320223A5070215876 @default.
• W4306320223 hasBestOaLocation W43063202231 @default.
• W4306320223 hasConcept C126322002 @default.
• W4306320223 hasConcept C127413603 @default.
• W4306320223 hasConcept C141071460 @default.
• W4306320223 hasConcept C164705383 @default.
• W4306320223 hasConcept C206179267 @default.
• W4306320223 hasConcept C23131810 @default.
• W4306320223 hasConcept C2776301958 @default.
• W4306320223 hasConcept C2778661090 @default.
• W4306320223 hasConcept C2779161974 @default.
• W4306320223 hasConcept C2780290652 @default.
• W4306320223 hasConcept C2780645631 @default.
• W4306320223 hasConcept C3017811039 @default.
• W4306320223 hasConcept C71924100 @default.
• W4306320223 hasConcept C78519656 @default.
• W4306320223 hasConceptScore W4306320223C126322002 @default.
• W4306320223 hasConceptScore W4306320223C127413603 @default.
• W4306320223 hasConceptScore W4306320223C141071460 @default.
• W4306320223 hasConceptScore W4306320223C164705383 @default.
• W4306320223 hasConceptScore W4306320223C206179267 @default.
• W4306320223 hasConceptScore W4306320223C23131810 @default.
• W4306320223 hasConceptScore W4306320223C2776301958 @default.
• W4306320223 hasConceptScore W4306320223C2778661090 @default.
• W4306320223 hasConceptScore W4306320223C2779161974 @default.
• W4306320223 hasConceptScore W4306320223C2780290652 @default.
• W4306320223 hasConceptScore W4306320223C2780645631 @default.
• W4306320223 hasConceptScore W4306320223C3017811039 @default.
• W4306320223 hasConceptScore W4306320223C71924100 @default.
• W4306320223 hasConceptScore W4306320223C78519656 @default.
• W4306320223 hasIssue "Supplement_2" @default.
• W4306320223 hasLocation W43063202231 @default.
• W4306320223 hasOpenAccess W4306320223 @default.
• W4306320223 hasPrimaryLocation W43063202231 @default.
• W4306320223 hasRelatedWork W1972269502 @default.
• W4306320223 hasRelatedWork W2126858523 @default.
• W4306320223 hasRelatedWork W2206334670 @default.
• W4306320223 hasRelatedWork W2272431884 @default.
• W4306320223 hasRelatedWork W2319489406 @default.
• W4306320223 hasRelatedWork W2409400224 @default.
• W4306320223 hasRelatedWork W3106370438 @default.
• W4306320223 hasRelatedWork W3132289493 @default.
• W4306320223 hasRelatedWork W3213840722 @default.
• W4306320223 hasRelatedWork W4236955258 @default.
• W4306320223 hasVolume "43" @default.
• W4306320223 isParatext "false" @default.
• W4306320223 isRetracted "false" @default.
• W4306320223 workType "article" @default.